MicroRNA-based interventions to prevent progression from lung preneoplasia to adenocarcinoma
MicroRNA-based interventions to prevent progression from lung preneoplasia to adenocarcinoma
批准号:
9379210
负责人:
Roy S Herbst
金额:
$20.76万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-08-26 至 2019-07-31
关键词:
AddressAdenocarcinomaAlpha CellAtypical adenomatous hyperplasiaAutomobile DrivingBenignBindingBiological AssayBiological MarkersCancer EtiologyCancer PatientCellsCharacteristicsCritical PathwaysDNA Sequence AlterationDataDetectionDevelopmentDiagnosisDimensionsDiseaseEpidermal Growth Factor ReceptorEventFormalinFrequenciesGene ExpressionGenetic TranscriptionGoalsGrowthHeterogeneityInflammationInflammation MediatorsInflammatoryInterventionKRAS2 geneLaboratoriesLesionLinkLungLung AdenocarcinomaLung NeoplasmsMaintenanceMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of lungMediatingMessenger RNAMicroRNAsModelingMolecular ProfilingMutant Strains MiceNeoplasmsNon-Small-Cell Lung CarcinomaNormal tissue morphologyNuclearOncogenicOrganoidsParaffin EmbeddingPathologyPathway interactionsPatientsPlayPremalignantPremalignant CellPrimary NeoplasmResearchRoleSerumSignal PathwaySignal TransductionSiteSpecimenStructureStructure of parenchyma of lungSurvival RateTP53 geneTechniquesTestingTherapeuticTissuesTranscriptTransgenic MiceTumor InitiatorsTumor TissueUntranslated RNAUp-Regulationadenomabasecancer stem cellgenetic profilingimprovedinhibitor/antagonistinnovationlocked nucleic acidmortalitymouse modelnanoparticleneoplastic cellnoveloverexpressionprecursor cellpreventprogramsresponsestandard of carestemnesstreatment responsetumortumor initiationtumor progressiontumorigenesis
中文摘要
项目摘要
这项提案的标题是“基于MicroRNA的干预措施,以防止从肺癌前病变进展到
腺癌”对PQ 1有反应。
肺癌是全球癌症相关死亡的最常见原因。尽管在检测方面取得了进展
和护理标准的提高,肺癌患者的总体生存率仍然很低(5)。
这种低生存率可能是由于诊断时疾病的相对晚期。如果肺
癌症可以在进展到晚期之前的癌前阶段被识别和停止,我们
可以提高患者的生存率。然而,很少有人知道的生物标志物区分癌前病变
从正常组织和分子驱动癌前病变的开始和发展。最近的证据
显示肿瘤内细胞异质性有助于肿瘤的发生和癌症的进展,包括
肺癌6例。肿瘤起始细胞(TIC)或癌症干细胞是大量肿瘤细胞的亚群
它可以概括整个肿瘤的异质结构,并在功能上驱动肿瘤发生。核
因子-κB(NF-κB)是炎症反应的关键介质,最近被认为是
一个司机的交通信息中心(7)。最近,已经发现炎症可以改变一些
microRNAs(miRNAs),包括致癌miR-21的上调(8)。miRNAs是非编码RNA
属于一类新的调节分子,其通过结合互补的
同时在多个靶信使RNA(mRNA)转录本上定位(9)。然而,信号事件
将癌症干细胞相关的miRNA与炎性细胞中的癌前病变起始和进展联系起来,
微环境有待进一步研究。我们假设炎症诱导的miRNA表达失调可能与炎症相关。
TIC可能在KRASmut或表皮生长因子受体中驱动癌前病变的发生和进展
(EGFRmut)肺腺癌患者,对此的更深入了解可能会发现新的靶点
用于基于miRNA的治疗。在目标1中,我们将描述肺肿瘤前病变中的miRNA特征,
组织中在目标2中,我们将研究miRNA抑制剂或模拟物在预防肿瘤进展中的作用,
肺内的癌前病变至癌形成。在这些研究结束时,我们将产生一个新的肿瘤
类器官模型,开发了可用于治疗癌前病变和预防恶性肿瘤的miRNA疗法,
进展,以及获得有关TIC和炎症生态位作用的创新信息。
肿瘤前病变的发生和发展。
英文摘要
PROJECT SUMMARY
This proposal titled “MicroRNA-based interventions to prevent progression from lung preneoplasia to
adenocarcinoma” is responsive to PQ1.
Lung cancer is the most common cause of cancer-related mortality worldwide. Despite advances in detection
and improvements to standard of care, the overall survival rate for lung cancer patients remains very low (5).
This poor survival rate is probably due to the relatively advanced stage of the disease at diagnosis. If lung
cancer could be identified and stopped at a preneoplastic stage prior to progression into advanced stage, we
could improve the patients' survival. However, little is known about the biomarkers distinguishing preneoplasia
from normal tissues and the molecules driving preneoplasia initiation and progression. Recent evidence has
shown that intratumor cellular heterogeneity contributes to tumor initiation and progression of cancer, including
lung cancer (6). Tumor-initiating cells (TICs) or cancer stem cells are a subpopulation of the bulk of tumor cells
that can recapitulate the whole tumor's heterogeneous structures and functionally drive tumorigenesis. Nuclear
factor-κB (NF-κB) is the key mediators of the inflammation response and has been recently been implicated as
a driver of TICs (7). More recently, it has been found that inflammation can change expression of some
microRNAs (miRNAs), including upregulation of oncogenic miR-21 (8). MiRNAs are non-coding RNAs
belonging to a novel class of regulatory molecules that control gene expression by binding to complementary
sites on multiple target messenger RNA (mRNA) transcripts simultaneously (9). However, the signaling events
that link cancer stemness-related miRNAs to preneoplasia initiation and progression in inflammatory
microenvironments remain to be charted. We hypothesize that inflammation induced miRNA dysregulation on
TICs might drive preneoplasia initiation and progression in KRASmut or epidermal growth factor receptor
(EGFRmut) lung adenocarcinoma patients, and that a deeper understanding of this may identify novel targets
for miRNA-based therapeutics. In Aim 1, we will characterize a miRNA signature in preneoplasia in lung
tissues. In Aim 2, we will investigate roles of miRNA inhibitors or mimics in preventing progression from
preneoplasia to neoplasia in lung. At the conclusion of these studies, we will have generated a new tumor
organoid model, developed miRNA therapeutics useful in curing preneoplasia and preventing malignant
progression, as well as gained innovative information regarding roles of both TICs and the inflammatory niche
in preneoplasia initiation and progression.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Yale Cancer Center NCTN LAPS
-
批准号:10359158
-
项目类别:
-
资助金额:$48.49万
-
财政年份:2019
-
负责人:Roy S Herbst
-
依托单位:
Yale Cancer Center NCTN LAPS
-
批准号:10582614
-
项目类别:
-
资助金额:$87.91万
-
财政年份:2019
-
负责人:Roy S Herbst
-
依托单位:
Yale Cancer Center NCTN LAPS
-
批准号:10734497
-
项目类别:
-
资助金额:$12.0万
-
财政年份:2019
-
负责人:Roy S Herbst
-
依托单位:
Yale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung Cancer
-
批准号:10203850
-
项目类别:
-
资助金额:$200.37万
-
财政年份:2015
-
负责人:Roy S Herbst
-
依托单位:
Yale SPORE in Lung Cancer Developmental Research Program
-
批准号:10203857
-
项目类别:
-
资助金额:$8.96万
-
财政年份:2015
-
负责人:Roy S Herbst
-
依托单位:
Yale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung Cancer
-
批准号:9338869
-
项目类别:
-
资助金额:$71.51万
-
财政年份:2015
-
负责人:Roy S Herbst
-
依托单位:
Yale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung Cancer
-
批准号:9767058
-
项目类别:
-
资助金额:$213.48万
-
财政年份:2015
-
负责人:Roy S Herbst
-
依托单位:
Yale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung Cancer
-
批准号:8931829
-
项目类别:
-
资助金额:$218.5万
-
财政年份:2015
-
负责人:Roy S Herbst
-
依托单位:
Core A: Administrative Core
-
批准号:10203851
-
项目类别:
-
资助金额:$15.48万
-
财政年份:2015
-
负责人:Roy S Herbst
-
依托单位:
Administrative Core
-
批准号:8931832
-
项目类别:
-
资助金额:$86.07万
-
财政年份:2015
-
负责人:Roy S Herbst
-
依托单位:
Personalizing NSCLC Therapy: Exploiting KRAS activated pathways
-
批准号:8920514
-
项目类别:
-
资助金额:$55.45万
-
财政年份:2011
-
负责人:Roy S Herbst
-
依托单位:
Personalizing NSCLC Therapy: Exploiting KRAS activated pathways
-
批准号:8707401
-
项目类别:
-
资助金额:$54.12万
-
财政年份:2011
-
负责人:Roy S Herbst
-
依托单位:
Personalizing NSCLC Therapy: Exploiting KRAS activated pathways
-
批准号:8517039
-
项目类别:
-
资助金额:$52.79万
-
财政年份:2011
-
负责人:Roy S Herbst
-
依托单位:
Personalizing NSCLC Therapy: Exploiting KRAS activated pathways
-
批准号:8332772
-
项目类别:
-
资助金额:$56.49万
-
财政年份:2011
-
负责人:Roy S Herbst
-
依托单位:
Personalizing NSCLC Therapy: Exploiting KRAS activated pathways
-
批准号:8186504
-
项目类别:
-
资助金额:$58.43万
-
财政年份:2011
-
负责人:Roy S Herbst
-
依托单位:
U10 Ful Member Application Affiliated with SWOG
-
批准号:7555078
-
项目类别:
-
资助金额:$21.59万
-
财政年份:2004
-
负责人:Roy S Herbst
-
依托单位:
U10 Full Member Application Affiliated with SWOG
-
批准号:7767468
-
项目类别:
-
资助金额:$32.57万
-
财政年份:2004
-
负责人:Roy S Herbst
-
依托单位:
Phase I trial of antiangiogenic agent SU6668 in Pt w solid tumors
-
批准号:6563965
-
项目类别:
-
资助金额:$29.68万
-
财政年份:2002
-
负责人:Roy S Herbst
-
依托单位:
Core--Clinical trials
-
批准号:6563968
-
项目类别:
-
资助金额:$29.68万
-
财政年份:2002
-
负责人:Roy S Herbst
-
依托单位:
Core--Clinical trials
-
批准号:6499818
-
项目类别:
-
资助金额:$29.68万
-
财政年份:2001
-
负责人:Roy S Herbst
-
依托单位:
国内基金
海外基金
大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
-
批准号:30840003
-
项目类别:专项基金项目
-
资助金额:12.0万元
-
批准年份:2008
-
负责人:焦宇飞
-
依托单位: